The biopharma M&A wave is not a one-quarter story. The structural pressures pushing large pharmaceutical companies toward acquisitions are intensifying, and the data from early 2026 suggests the pace is holding.
According to IQVIA, aggregate biopharma M&A deal value more than doubled in 2025, rising 133% year-over-year to reach $133 billion for the full year, the second-highest level in five years, with deal count hitting 50, the highest since 2021. Then March 2026 removed any doubt about momentum. In a 12-day window at the end of the month, biopharma companies closed seven transactions each worth more than $1 billion, with a combined headline value of $29 billion.
#The Patent Cliff Is the Structural Engine
The force driving this activity is well-defined. By 2030, more than $200 billion in biopharma revenues will face loss-of-exclusivity exposure, with another $200 billion at risk in the early 2030s. For large-cap companies, the arithmetic is straightforward: acquire external innovation or watch revenue erode as generics and biosimilars displace branded products.
Bristol Myers Squibb faces what analysts describe as the largest growth gap among its large-cap peers, with approximately $38 billion in future at-risk revenue. Merck is preparing for Keytruda's U.S. patent exposure in 2028, a product that generated $31.7 billion in sales in 2025, according to the company's full-year results. These are not edge cases. By 2026, eight of the 13 largest pharmaceutical firms, representing 55% of global market value, could see 30% or more of their revenue put at risk.
Acquiring late-stage biotech assets is the fastest response available. Smaller companies with mature development programs or products already approaching market offer a faster, lower-risk route to bridge revenue gaps than internal development alone.
#Oncology, CNS, and Obesity Drive Therapeutic Focus
The deals are concentrated in therapeutic categories where commercial demand is clearest. According to EY data, the central nervous system and neurology segment captured $30.7 billion in biopharma M&A value in 2025, overtaking oncology at $23.5 billion. Johnson and Johnson's $14.6 billion acquisition of Intra-Cellular Therapies anchored the CNS total, adding Caplyta to its neuroscience portfolio across schizophrenia, bipolar depression, and major depressive disorder.
Obesity and metabolic disease have become the second major battleground. More than 120 metabolic assets are currently in development across 60 companies, according to PitchBook, creating a deep pool of potential targets. A bidding war between Pfizer and Novo Nordisk for weight loss developer Metsera illustrated the competitive intensity at the top of the market. Cardiometabolic drug portfolios are now among the most sought-after assets in the sector.
Citeline biopharma analyst Amanda Micklus points to a broader range of modalities in demand, including bispecific antibodies in immuno-oncology, genome editing, and in vivo CAR-T therapies, alongside oncology and metabolic disease candidates.
#Small-Cap Biotech Valuations Create Acquisition Conditions
Large acquirers are not only motivated by need to replenish their drug portfolios. They are operating in an unusually favorable pricing environment for targets. The XBI, a widely tracked biotech index, hit an 18-month low in April 2025 before recovering 75% by December, reflecting a sector that moved from distressed to dealable inside a single year. For companies with strong balance sheets, these conditions reduce the cost of acquisition substantially.
Industry observers note that pharma companies are willing to pay up even at higher valuations, given their firepower and the finite window before patent revenues decline. Big pharma's collective deal capacity now stands at an estimated $1.3 trillion across the top 25 companies, one of the highest figures on record, and the 2025 dealmaking surge did not materially deplete that reserve.
#Risks That Could Slow the Cycle
The pace of dealmaking is not without constraints. Regulatory uncertainty remains a variable. FDA staffing changes and shifting drug-pricing policy in the U.S. created hesitation in the first half of 2025. It was only when companies gained more clarity on the regulatory and pricing landscape that activity heated up, with eight of the ten largest 2025 deals executing in the second half of the year.
Geopolitics adds further complexity. The BIOSECURE Act, passed by Congress in December 2025 as part of the National Defense Authorization Act, adds uncertainty to cross-border deal structures, particularly those involving Chinese biotech assets. Companies pursuing global strategies will need to navigate a more fragmented environment than the previous deal cycle required.
Valuation pressure on targets can also run the other way. As deal activity increases, premium expectations among biotech management teams and investors tend to rise, compressing return profiles for acquirers.
The structural case for continued biopharma M&A is well-supported by data. The patent cliff has a known timeline, acquirer balance sheets are strong, and the pool of available targets remains deep. For investors tracking this sector, the more relevant question is not whether dealmaking continues, but which therapeutic categories and asset types attract the most durable acquisition interest over the next 24 months.